Baxalta Inc

Most Recent

  • uploads///Graph Part  Dec
    Company & Industry Overviews

    XLV Was Trading Higher after Paying Dividends

    The Health Care Select Sector ETF (XLV) rose by 1.1% and closed at $72.38 on December 23. XLV is trading well above its 20-day, 50-day, and 100-day moving averages.

    By Peter Neil
  • uploads///BXLT SHPG financial highlights
    Miscellaneous

    Parsing the Baxalta–Shire Material Adverse Effect Clause, Part 1

    The standard MAE clause basically says that anything bad that happens to Baxalta and delays or ruins the economics of the deal is a MAE, with some exceptions.

    By Brent Nyitray, CFA, MBA
  • uploads///Graph
    Earnings Report

    Biogen’s Hemophilia Drugs Continue to Capture Market Share in 1Q16

    Biogen’s hemophilia drugs, Alprolix and Eloctate, continued to capture market share in 1Q16.

    By Margaret Patrick
  • uploads///sales Q segmentwise
    Earnings Report

    How Did Novo’s 2 Segments Perform in 1Q16?

    Novo Nordisk’s two business segments are diabetes and obesity care and biopharmaceuticals. In 1Q16, they saw annual sales growth of 6% and 15%, respectively.

    By Jillian Dabney
  • uploads///hemophilia market size
    Company & Industry Overviews

    Could Baxalta Maintain Its Leadership in the Hemophilia Space?

    Baxalta’s (BXLT) hemophilia portfolio comprises of Advate, Adynovate, Rixubis, Recombinate, Hemofil M, Immunate, Immunine, and Prothromplex Total.

    By Jillian Dabney
  • uploads///hemophilia drugs
    Company & Industry Overviews

    What Are the Current Treatment Options for Hemophilia?

    Hemophilia treatment primarily includes factor replacement therapy and prolonged half-life therapy such as factor VIII or factor IX infusion.

    By Jillian Dabney
  • uploads///Graph pipeline
    Company & Industry Overviews

    BMN 270: A Big Valuation Catalyst for BioMarin

    On March 1, 2016, BioMarin received orphan drug designation for BMN 270 from the FDA. BioMarin’s stock jumped by about 6.96% the same day.

    By Jillian Dabney
  • uploads///Graph Part  Dec
    Company & Industry Overviews

    Baxalta Rose on FDA’s Approval of Vonvendi

    Baxalta (BXLT) rose by 0.7% on December 9, 2015. The stock moved up as the FDA (US Food and Drug Administration) approved its drug Vonvendi.

    By Peter Neil
  • uploads///capital allocation
    Company & Industry Overviews

    Interpreting Baxter’s Recent Dividend Announcement

    On November 14, 2017, Baxter International (BAX) announced a quarterly dividend of $0.16 per share, payable on January 2, 2018.

    By Sarah Collins
  • uploads///orkambi revenue
    Earnings Report

    A Promising Uptake for Vertex’s Orkambi

    It’s been nine months since Vertex Pharmaceuticals (VRTX) launched Orkambi. Out of the 8,500 eligible patients, around 5,500 are using the drug.

    By Jillian Dabney
  • uploads///bioverative product pipeline
    Company & Industry Overviews

    After Spinning Off Hemophilia Business, What’s Next for Biogen?

    Biogen (BIIB) announced the spin-off of its hemophilia business on May 3, 2016.

    By Sarah Collins
  • uploads///Part  Graph
    Company & Industry Overviews

    BioMarin Withdraws Application for Kyndrisa: Stock Falls 2.5%

    As of June 1, 2016, BioMarin Pharmaceutical (BMRN) was the most underperforming stock among the large-cap stocks of the SPDR S&P Biotech ETF (XBI).

    By Peter Neil
  • uploads///Part  Graph
    Company & Industry Overviews

    Shire’s Shareholders Approve Baxalta Merger: What’s Next?

    Shire (SHPG) performed the worst among the large-cap stocks of the iShares Nasdaq Biotechnology ETF (IBB) on May 27, 2016.

    By Peter Neil
  • uploads///oncaspar
    Company & Industry Overviews

    What Does the Future Hold for Oncaspar?

    Baxalta’s (BXLT) oncology portfolio came into existence in 2015 after the company’s acquisition of Oncaspar.

    By Jillian Dabney
  • uploads///hematology
    Company & Industry Overviews

    How Is Baxalta Leading the Hematology Space?

    Baxalta’s (BXLT) hematology segment includes hemophilia and inhibitor therapies.

    By Jillian Dabney
  • uploads///immunology portfolio
    Company & Industry Overviews

    Baxalta: How Is Its Immunology Portfolio Performing?

    Baxalta’s (BXLT) immunology drugs comprise immunoglobulin therapies and biotherapeutics.

    By Jillian Dabney
  • uploads///hemophilia
    Company & Industry Overviews

    Could Gene Therapy Be a Next-Generation Treatment for Hemophilia?

    Gene therapy is the emerging platform for hemophilia care. If approved, it would be a paradigm.

    By Jillian Dabney
  • uploads///product portfolio
    Company & Industry Overviews

    A Look at Baxalta’s Product Segments

    Baxalta’s (BXLT) product portfolio can be divided into three parts: hematology, immunology, and oncology.

    By Jillian Dabney
  • uploads///Share price after shire baxalta deal
    Company & Industry Overviews

    The Shire-Baxalta Merger: A Look at the Details

    Following news of the Shire-Baxalta merger, Baxalta’s share price rose and Shire’s share price fell.

    By Jillian Dabney
  • uploads///acquisitions
    Company & Industry Overviews

    Baxalta: Growth through Acquisitions

    In March 2013, Baxalta acquired Inspiration BioPharmaceuticals. Through this acquisition, it gained the investigational drug Obizur and related assets.

    By Jillian Dabney
  • uploads///Part  Graph
    Company & Industry Overviews

    XLV Mid-Cap Stocks: Why Mallinckrodt Fell Due to Profit-Booking

    Mallinckrodt (MNK) fell by 4.5% due to profit-booking. It closed at $58.40. The stock remained volatile on the backdrop of Valeant’s (VRX) episode.

    By Peter Neil
  • uploads///Part  Graph
    Company & Industry Overviews

    Allergan Fell on the Possible Termination of Pfizer Merger

    The Dow Jones Industrial Average went down by 0.75% on April 5, 2016, as the US markets followed the global sell-off trend.

    By Peter Neil
  • uploads///Part  Graph
    Company & Industry Overviews

    XBI Large-Cap News: Amid Beatdowns, Regeneron Has an Announcement

    All 11 large-cap stocks that XBI holds in its portfolio declined on March 23. Large-cap stocks account for 19.3% of XBI’s portfolio.

    By Peter Neil
  • uploads///strategic initiatives
    Company & Industry Overviews

    How Baxter’s Biosciences Spin-off into Baxalta Improved Its Valuation

    On July 1, 2015, Baxter separated its Biosciences division into a new entity named Baxalta in an effort to divest risky segments and streamline operations.

    By Sarah Collins
  • uploads///Graph
    Company & Industry Overviews

    Demand for Hemophilia Drugs Could Grow Biogen’s Revenue in 2016

    In 2016, Biogen (BIIB) expects strong growth in demand for Eloctate, its hemophilia drug. Eloctate is expected to be adopted by more hemophilia patients who require long-acting therapies.

    By Margaret Patrick
  • uploads///BXLT SHPG combination
    Miscellaneous

    The Baxalta–Shire merger: Basics of Shire Pharmaceuticals

    Shire is a biopharmaceutical company that focuses on rare diseases. Shire is best known for its treatments in ADHD, and the market here is quite large.

    By Brent Nyitray, CFA, MBA
  • uploads///BXLT SHPG synergies
    Miscellaneous

    Growth and Synergies Drive the Baxalta–Shire Merger

    The Baxalta–Shire merger could create the top platform for rare diseases in the world. Baxalta brings Advate, a treatment for hemophilia, a rare blood disease.

    By Brent Nyitray, CFA, MBA
  • uploads///BXLT SHPG Spread
    Miscellaneous

    Shire Seals the Deal with Baxalta after a Long Negotiation

    On Monday, January 11, 2016, Shire agreed to buy Baxalta for a combination of cash and stock. BXLT shareholders will receive $18.0 cash per share of BXLT.

    By Brent Nyitray, CFA, MBA
  • uploads///Vanguard  Index Fund Investor Class VFINX
    Company & Industry Overviews

    US Stock Indexes Fell in December amid Falling Oil Prices

    Let’s see why US stock indexes fell. The three US equity indexes that we review in this December recap series fell from November 30 to December 31, 2015.

    By Lynn Noah
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.